IDEAMLD™
Intrathecal Delivery of the Enzyme Arylsulfatase A in MLD

Shire
300 Shire Way
Lexington, MA 02421 USA

Date: October 1, 2012

Dear MLD Patient Advocacy Organization:

As you know, Shire Human Genetic Therapies, Inc. (Shire HGT) is sponsoring a clinical trial to evaluate the safety of an experimental intrathecal enzyme replacement therapy for patients with metachromatic leukodystrophy (MLD). The study (HGT-MLD-070) is designed for 40 weeks with the primary goal to evaluate safety of ascending doses of the investigational drug in patients using a surgically implanted device.

We would like to inform you that an additional site for this study is now open in France. Further details are available at www.clinicaltrials.gov (keyword metachromatic leukodystrophy; NCT01510028). With questions about eligibility, please direct interested patients and families to their physician. We appreciate your partnership in commitment to the MLD community, and we hope this information is helpful to you and your members.

Sincerely,

Amy Fisher, MS, CGC
Associate Director, Scientific Patient Communications
Shire HGT Global Medical Affairs
www.shire.com